Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To...
Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To...
Aptose Announces Publication Of Preclinical Data Demonstrating Tuspetinib's Unique Mechanism Of Action And Synthetic Lethality On AML Cells When Combined With Venetoclax In AACR Journal; Tuspetinib Prolongs Survival In Multiple AML Models Resistant To Other Drugs; Findings Suggest TUS Will Demonstrate Broad Antileukemic Activity Across AML Patients
Aptose宣布在AACR期刊上发布前临床数据，证明Tuspetinib的独特作用机制以及与Venetoclax联用时对AML细胞的合成致死性；Tuspetinib在对其他药物耐药的多个AML模型中延长生存期；研究结果表明TUS将在AML患者中展示广泛的抗白血病活性。
- Peer-reviewed publication details unique TUS mechanism of action
- TUS+VEN combination synthetic lethality overcomes resistance to VEN
- Tuspetinib prolongs survival in multiple AML models resistant to other drugs
- Findings suggest TUS will demonstrate broad antileukemic activity across AML patients
-
TUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling
- 经过同行评审的出版物详细介绍了TUS的独特作用机制。
- TUS+VEN组合的合成致死性克服了对VEN的耐药性。
- Tuspetinib在对其他药物耐药的多个AML模型中延长生存期。
- 研究结果表明TUS将在AML患者中展示广泛的抗白血病活性。
- 目前正在招募新诊断AML患者的TUS+VEN+AZA三重前线治疗。
SAN DIEGO and TORONTO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the publication of preclinical data for Aptose's lead hematology compound tuspetinib (TUS) in Cancer Research Communications, a journal of the American Association for Cancer Research (AACR), available online now (link).
圣地亚哥和多伦多，2024年12月12日（环球新闻通讯社）-- Aptose Biosciences Inc.（"Aptose"或"公司"）（纳斯达克：APTO，TSX：APS），一家临床阶段的精准肿瘤学公司，正在开发高度差异化的靶向药物以治疗血液恶性肿瘤，今天宣布在美国癌症研究协会（AACR）期刊《抗癌医药通讯》上发布Aptose的主要血液学化合物Tuspetinib（TUS）的前临床数据，目前在线可用（链接）。
The publication, entitled "Preclinical development of tuspetinib for the treatment of acute myeloid leukemia," is the first preclinical profiling of tuspetinib, a well-tolerated, once daily, oral kinase inhibitor currently in clinical development for treatment of acute myeloid leukemia (AML). The publication defines TUS activities on select oncogenic signaling targets, demonstrates enhanced activity and safety of TUS when combined with other agents, and illustrates synthetic lethality when combined with venetoclax (VEN). Pharmacokinetic and toxicology studies revealed that TUS is readily absorbed and achieves plasma concentrations sufficient to inhibit the target kinases, it has a plasma half-life that supports once daily dosing, and it demonstrates a favorable safety profile.
这篇题为《Tuspetinib治疗急性髓性白血病的前临床开发》的出版物是对Tuspetinib的首次前临床分析，这是一种耐受良好的、每日一次的口服激酶抑制剂，目前正在进行急性髓性白血病（AML）的临床开发。该出版物定义了TUS对特定肿瘤信号靶标的活性，展示了TUS与其他药物联用时的增强活性和安全性，并说明了TUS与Venetoclax（VEN）联用时的合成致死性。药代动力学和毒理学研究表明，TUS被快速吸收并达到足以抑制目标激酶的血浆浓度，其血浆半衰期支持每日一次给药，并且显示出良好的安全性特征。
Aptose is now enrolling newly diagnosed AML patients in a Phase 1/2 clinical study to receive the tuspetinib + venetoclax + azacitidine (TUS+VEN+AZA) triplet combination (NCT03850574). Clinical studies in patients with relapsed or refractory AML receiving TUS single agent or the TUS+VEN combination have been completed.
Aptose现在正在招募新诊断的急性髓性白血病（AML）患者，参与一项1/2期临床研究，以接受tuspetinib + venetoclax + azacitidine（TUS+VEN+AZA）三联组合（NCT03850574）。针对复发或难治性AML患者接受TUS单药或TUS+VEN组合的临床研究已完成。
